On May 20, Kanglong Chemical announced that it has reached a comprehensive strategic cooperation with AstraZeneca China on integrated R&D and commercial production services throughout the entire process of drug discovery, pre-clinical and clinical development, and investment in innovative drug research and development, including small molecules, macromolecules, and cell and gene therapy drugs. At the same time, Kanglong Chemical plans to invest an additional 91 million yuan in the Wuxi AstraZeneca CICC Venture Capital Fund in the near future. The two sides will give full play to the resources and experience advantages of the industry-leading healthcare sector and the entire global industry chain to help innovative medical enterprises grow.
5月20日康龙化成宣布与阿斯利康中国就包括小分子、大分子和细胞与基因治疗药物在内的贯穿药物发现、临床前及临床开发全流程的研发和商业化生产一体化服务以及创新药研发领域投资达成全面战略合作同时康龙化成拟于近日向无锡阿斯利康中金创业投资基金追加投资9100万元。双方将充分发挥行业领先的医疗健康领域及全球化全产业链的资源和经验优势助力创新医疗企业成长。
On May 20, Kanglong Chemical announced that it has reached a comprehensive strategic cooperation with AstraZeneca China on integrated R&D and commercial production services throughout the entire process of drug discovery, pre-clinical and clinical develop
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.